Mechanism of Action of Ezetimibe
Ezetimibe reduces blood cholesterol by selectively inhibiting the Niemann-Pick C1-Like 1 (NPC1L1) protein, a sterol transporter located at the brush border of the small intestine that is responsible for cholesterol absorption. 1, 2
Molecular Target and Site of Action
The primary molecular target is the NPC1L1 protein, which actively facilitates the uptake of both dietary and biliary cholesterol (as well as phytosterols) from the intestinal lumen into enterocytes. 1, 2, 3
Ezetimibe localizes specifically at the brush border of the small intestine, where it blocks the NPC1L1-mediated cholesterol uptake process. 2, 4
The drug inhibits approximately 54% of intestinal cholesterol absorption compared to placebo, as demonstrated in clinical trials. 2
Mechanism at the Cellular Level
Ezetimibe prevents the sterol-induced internalization of NPC1L1 protein, blocking its incorporation into clathrin-coated vesicles that would normally transport cholesterol into the enterocyte. 5
Under normal conditions, cholesterol promotes the endocytosis of NPC1L1 through a clathrin/AP2-mediated pathway, but ezetimibe disrupts this vesicular endocytosis process, thereby preventing cholesterol from entering the cell. 5
Downstream Effects on Cholesterol Metabolism
By blocking intestinal cholesterol absorption, ezetimibe decreases the delivery of intestinal cholesterol to the liver, which depletes hepatic cholesterol stores. 2
This hepatic cholesterol depletion triggers an upregulation of LDL receptors on hepatocyte surfaces, resulting in increased clearance of LDL cholesterol from the bloodstream. 2
The net effect is a reduction in total cholesterol, LDL-C, apolipoprotein B, and non-HDL cholesterol levels. 2
Selectivity and Specificity
Ezetimibe is highly selective for cholesterol absorption and does not affect the absorption of fat-soluble vitamins (A, D, E), triglycerides, or bile acids. 2, 4
The drug does not impair adrenocortical steroid hormone production, maintaining normal endocrine function. 2
Unlike statins that inhibit hepatic cholesterol synthesis, ezetimibe works exclusively at the intestinal level, making it complementary to statin therapy with a synergistic effect when used in combination. 1, 4
Clinical Efficacy
As monotherapy, ezetimibe reduces LDL-C by approximately 18%, while in combination with statins it provides an incremental reduction of approximately 25%. 1
The IMPROVE-IT trial demonstrated that adding ezetimibe to statin therapy in patients with acute coronary syndrome resulted in significant reductions in cardiovascular death, nonfatal MI, unstable angina requiring hospitalization, coronary revascularization, and nonfatal stroke over 6 years of follow-up. 1